Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aveanna Healthcare Holdings (AVAH) Gains from Sales and Divestitures (2022 - 2026)

Aveanna Healthcare Holdings (AVAH) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $688865.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures rose 123.62% year-over-year to $688865.0, compared with a TTM value of $688865.0 through Dec 2024, up 123.62%, and an annual FY2024 reading of $688865.0, up 123.62% over the prior year.
  • Gains from Sales and Divestitures was $688865.0 for Q4 2024 at Aveanna Healthcare Holdings, up from $308055.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $688865.0 in Q4 2024 and bottomed at $308055.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $439324.3, with a median of $321053.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures decreased 4.05% in 2023, then surged 123.62% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $321053.0 in 2022, then fell by 4.05% to $308055.0 in 2023, then surged by 123.62% to $688865.0 in 2024.
  • Business Quant data shows Gains from Sales and Divestitures for AVAH at $688865.0 in Q4 2024, $308055.0 in Q4 2023, and $321053.0 in Q4 2022.